Results 41 to 50 of about 4,164 (194)
Loss of Nmp4 optimizes osteogenic metabolism and secretion to enhance bone quality [PDF]
, 2019 A goal of osteoporosis therapy is to restore lost bone with structurally sound tissue. Mice lacking the transcription factor Nuclear Matrix Protein 4 (Nmp4, Zfp384, Ciz, ZNF384) respond to several classes of osteoporosis drugs with enhanced bone ...
Adaway, Michele +18 more
core +1 more source
The 2024 UK clinical guideline for the prevention and treatment of osteoporosis [PDF]
Summary: The National Osteoporosis Guideline Group (NOGG) has updated the revised UK guideline for the assessment and management of osteoporosis and the prevention of fragility fractures in postmenopausal women, and men age 50 years and older.
core +13 more sources
Romosozumab Use and Cardiovascular Events
Journal of Bone and Mineral Research, 2022 *
Fusaro Maria, Tripepi Giovanni
openaire +2 more sources
Osteocytes and Their Messengers as Targets for the Treatment of Multiple Myeloma [PDF]
, 2017 Osteocytes, the most abundant cells in the bone, orchestrate the function of osteoblasts and osteocytes to control physiological bone homeostasis. Accumulating evidence demonstrates that alteration of osteocyte function underlies the pathophysiology of ...
Delgado-Calle, Jesus
core +2 more sources
Bone Reports, 2021 Real-world data on the new anti-sclerostin antibody drug, romosozumab, remain scarce. There is a strong need to accumulate and analyze data on romosozumab treatment for such conditions as osteoporosis.
Tomonori Kobayakawa +6 more
doaj +1 more source
Biomechanical Computed Tomography analysis (BCT) for clinical assessment of osteoporosis. [PDF]
, 2020 The surgeon general of the USA defines osteoporosis as "a skeletal disorder characterized by compromised bone strength, predisposing to an increased risk of fracture." Measuring bone strength, Biomechanical Computed Tomography analysis (BCT), namely ...
Bouxsein, ML +6 more
core
Assessment of cardiovascular safety of anti-osteoporosis drugs [PDF]
, 2020 The incidence of osteoporosis and cardiovascular disease increases with age, and there are potentially shared mechanistic associations between the two conditions.
Al-Daghri, Nasser +18 more
core +6 more sources
Canadian Journal of Health Technologies, 2021 CADTH recommends that Evenity should be reimbursed by public drug plans for the treatment of osteoporosis in postmenopausal women if certain conditions are met. Evenity should only be covered to treat postmenopausal women with a history of osteoporosis-related fracture and who are likely to have such a fracture in the future and who have ...
openaire +3 more sources
Role of bone-anabolic agents in the treatment of breast cancer bone metastases [PDF]
, 2014 Skeletal metastases are an incurable complication afflicting the majority of patients who die from advanced breast cancer. They are most often osteolytic, characterized by net bone destruction and suppressed new bone formation. Life expectancy from first
Chirgwin, John M., Suvannasankha, Attaya
core +1 more source
Mutations in Known Monogenic High Bone Mass Loci Only Explain a Small Proportion of High Bone Mass Cases. [PDF]
, 2015 High bone mass (HBM) can be an incidental clinical finding; however, monogenic HBM disorders (eg, LRP5 or SOST mutations) are rare. We aimed to determine to what extent HBM is explained by mutations in known HBM genes.
Addison, Kathryn A +20 more
core +7 more sources